Hepatotoxicity and drug interactions in liver transplant candidates and recipients

Clinics in Liver Disease

Volumn 17, Issue 4, 2013, Pages 737-747

  Parikh, Neehar D ^a   Levitsky, Josh ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Calcineurin; DILI; Immunosuppressives; Medication

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; AZATHIOPRINE; BOCEPREVIR; CALCINEURIN INHIBITOR; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN A; DIDANOSINE; EFAVIRENZ; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; INTERFERON; ISONIAZID; MACROLIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NELFINAVIR; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; RALTEGRAVIR; RAPAMYCIN; RIBAVIRIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TACROLIMUS; TELAPREVIR; UNINDEXED DRUG; ZIDOVUDINE;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATTY LIVER; GRAFT RECIPIENT; HEADACHE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LEUKOPENIA; LIVER CIRRHOSIS; LIVER GRAFT; LIVER TOXICITY; LIVER TRANSPLANTATION; MIXED INFECTION; NAUSEA; PANCYTOPENIA; REVIEW; RISK ASSESSMENT; SEIZURE; SIDE EFFECT; SOMNOLENCE; THINKING; TOXIC HEPATITIS; TREMOR; TUBERCULOSIS;

CALCINEURIN; DILI; IMMUNOSUPPRESSIVES; MEDICATION;

ANTIVIRAL AGENTS; DRUG INTERACTIONS; DRUG-INDUCED LIVER INJURY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; PROTEASE INHIBITORS; TRANSPLANTATION;

EID: 84884967039     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.07.013     Document Type: Review

References (85)

1. Zimmerman H.J. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver 1999, Lippincott Williams & Wilkins, Philadelphia. 2nd edition.
2. Wang Y., Lin Z., Liu Z., et al. Aunifying ontology to integrate histological and clinical observations for drug-induced liver injury. Am J Pathol 2013, 182(4):1180-1187.
3. Finucci G.F., Padrini R., Piovan D., et al. Verapamil pharmacokinetics and liver function in patients with cirrhosis. Int J Clin Pharmacol Res 1988, 8(2):123-126.
4. Weiler S., Zoller H., Graziadei I., et al. Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis. Antimicrob Agents Chemother 2007, 51(9):3459-3460.
5. Henriksen J.H. Volume adaptation in chronic liver disease: on the static and dynamic location of water, salt, protein and red cells in cirrhosis. Scand J Clin Lab Invest 2004, 64(6):523-533.
6. DeSanto N.G., Anastasio P., Loguercio C., et al. Creatinine clearance: an inadequate marker of renal filtration in patients with early posthepatitic cirrhosis (Child A) without fluid retention and muscle wasting. Nephron 1995, 70(4):421-424.
7. Zuckerman E., Slobodin G., Sabo E., et al. Quantitative liver-spleen scan using single photon emission computerized tomography (SPECT) for assessment of hepatic function in cirrhotic patients. JHepatol 2003, 39(3):326-332.
8. Villeneuve J.P., Pichette V. Cytochrome P450 and liver diseases. Curr Drug Metab 2004, 5(3):273-282.
9. Zollner G., Fickert P., Zenz R., et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001, 33(3):633-646.
10. Hu Y.F., Qiu W., Liu Z.Q., et al. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clin Exp Pharmacol Physiol 2006, 33(11):1093-1098.
11. Zochowska D., Wyzgal J., Paczek L. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients. Ann Transplant 2012, 17(3):36-44.
12. Luo G., Guenthner T., Gan L.S., et al. CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr Drug Metab 2004, 5(6):483-505.
13. Schroeder E.K., de Souza N., Santos D.S., et al. Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis. Curr Pharm Biotechnol 2002, 3(3):197-225.
14. Sotsuka T., Sasaki Y., Hirai S., et al. Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. InVivo 2011, 25(5):803-812.
15. Ranguelova K., Suarez J., Magliozzo R.S., et al. Spin trapping investigation of peroxide- and isoniazid-induced radicals in Mycobacterium tuberculosis catalase-peroxidase. Biochemistry 2008, 47(43):11377-11385.
16. Noda A., Noda H., Ohno K., et al. Spin trapping of a free radical intermediate formed during microsomal metabolism of hydrazine. Biochem Biophys Res Commun 1985, 133(3):1086-1091.
17. Fountain F.F., Tolley E., Chrisman C.R., et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005, 128(1):116-123.
18. LoBue P.A., Moser K.S. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003, 168(4):443-447.
19. Fernandez-Villar A., Sopena B., Vazquez R., et al. Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis 2003, 36(3):293-298.
20. McNeill L., Allen M., Estrada C., et al. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest 2003, 123(1):102-106.
21. Nolan C.M., Goldberg S.V., Buskin S.E. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999, 281(11):1014-1018.
22. Sharifzadeh M., Rasoulinejad M., Valipour F., et al. Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis [correction of antituberculosis] treatment. Pharmacol Res 2005, 51(4):353-358.
23. Ormerod L.P., Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis 1996, 77(1):37-42.
24. Yee D., Valiquette C., Pelletier M., et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003, 167(11):1472-1477.
25. Fernandez-Villar A., Sopena B., Fernandez-Villar J., et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2004, 8(12):1499-1505.
26. Schaberg T., Rebhan K., Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996, 9(10):2026-2030.
27. Wong W.M., Wu P.C., Yuen M.F., et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000, 31(1):201-206.
28. Saukkonen J.J., Cohn D.L., Jasmer R.M., et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006, 174(8):935-952.
29. de Castro L., do Brasil P.E., Monteiro T.P., et al. Can hepatitis B virus infection predict tuberculosis treatment liver toxicity? Development of a preliminary prediction rule. Int J Tuberc Lung Dis 2010, 14(3):332-340.
30. Ungo J.R., Jones D., Ashkin D., et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998, 157(6 Pt 1):1871-1876.
31. Sarma G.R., Immanuel C., Kailasam S., et al. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev Respir Dis 1986, 133(6):1072-1075.
32. Jones M., Nunez M. Liver toxicity of antiretroviral drugs. Semin Liver Dis 2012, 32(2):167-176.
33. Lamar Z.S., Nunez M. Higher risk of severe drug-induced liver injury among Hispanic HIV-infected patients after initiation of highly active antiretroviral therapy. JInt Assoc Physicians AIDS Care (Chic) 2011, 10(3):183-186.
34. Sulkowski M.S. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004, 38(Suppl 2):S90-S97.
35. Bonacini M. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection. Clin Infect Dis 2004, 38(Suppl 2):S104-S108.
36. den Brinker M., Wit F.W., Wertheim-van Dillen P.M., et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000, 14(18):2895-2902.
37. Gupta N.K., Lewis J.H. Review article: the use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther 2008, 28(9):1021-1041.
38. Balzarini J., Lee C.K., Herdewijn P., et al. Mechanism of the potentiating effect of ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficiency virus. JBiol Chem 1991, 266(32):21509-21514.
39. Vispo E., Mena A., Maida I., et al. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. JAntimicrob Chemother 2010, 65(3):543-547.
40. Rivero A., Mira J.A., Pineda J.A. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. JAntimicrob Chemother 2007, 59(3):342-346.
41. Macias J., Neukam K., Mallolas J., et al. Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients. HIV Clin Trials 2012, 13(2):61-69.
42. Pineda J.A., Neukam K., Mallolas J., et al. Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis. JInfect 2012, 64(2):204-211.
43. Mira J.A., Macias J., Giron-Gonzalez J.A., et al. Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C. JAntimicrob Chemother 2006, 58(1):140-146.
44. Dieterich D.T., Robinson P.A., Love J., et al. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004, 38(Suppl 2):S80-S89.
45. Sulkowski M.S., Thomas D.L., Chaisson R.E., et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000, 283(1):74-80.
46. Aceti A., Pasquazzi C., Zechini B., et al. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. JAcquir Immune Defic Syndr 2002, 29(1):41-48.
47. Monforte Ade A., Bugarini R., Pezzotti P., et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. JAcquir Immune Defic Syndr 2001, 28(2):114-123.
48. Duh M.S., Vekeman F., Korves C., et al. Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications. Pain Med 2010, 11(11):1718-1725.
49. Tegeder I., Lotsch J., Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 1999, 37(1):17-40.
50. Kuffner E.K., Green J.L., Bogdan G.M., et al. The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients-a multicenter randomized study. BMC Med 2007, 5:13.
51. Avins A.L., Manos M.M., Ackerson L., et al. Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study. Drug Saf 2008, 31(4):325-334.
52. Bhardwaj S.S., Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis 2007, 11(3):597-613. vii.
53. Chavez E., Castro-Sanchez L., Shibayama M., et al. Effects of acetyl salycilic acid and ibuprofen in chronic liver damage induced by CCl4. JAppl Toxicol 2012, 32(1):51-59.
54. Brown S.J., Desmond P.V. Hepatotoxicity of antimicrobial agents. Semin Liver Dis 2002, 22(2):157-167.
55. Andrade R.J., Lucena M.I., Kaplowitz N., et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006, 44(6):1581-1588.
56. Gundling F., Seidl H., Strassen I., et al. Clinical manifestations and treatment options in patients with cirrhosis and diabetes mellitus. Digestion 2013, 87(2):75-84.
57. Sembera S., Lammert C., Talwalkar J.A., et al. Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation. Liver Transpl 2012, 18(7):803-810.
58. Wiesner R.H., Fung J.J. Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl 2011, 17(Suppl 3):S1-S9.
59. Rostaing L., Saliba F., Calmus Y., et al. Review article: use of induction therapy in liver transplantation. Transplant Rev (Orlando) 2012, 26(4):246-260.
60. Scott L.J., McKeage K., Keam S.J., et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003, 63(12):1247-1297.
61. Ceschi A., Rauber-Luthy C., Kupferschmidt H., et al. Acute calcineurin inhibitor overdose: analysis of cases reported to a national poison center between 1995 and 2011. Am J Transplant 2013, 13(3):786-795.
62. Wu S.W., Chang H.R., Lai Y.R., et al. Non-life-threatening leukopenia in a renal transplant recipient with acute overdose of mycophenolate mofetil. Transplant Proc 2008, 40(10):3770-3771.
63. Bebarta V.S., Heard K., Nadelson C. Lack of toxic effects following acute overdose of cellcept (mycophenolate mofetil). JToxicol Clin Toxicol 2004, 42(6):917-919.
64. Kruger C., Jungert J., Schmitt-Grohe S., et al. Azathioprine ingestion with suicidal intent by an adolescent with chronic juvenile polyarthritis. Klin Padiatr 1998, 210(3):136-138. [in German].
65. Levitsky J. Next level of immunosuppression: drug/immune monitoring. Liver Transpl 2011, 17(Suppl 3):S60-S65.
66. Wallemacq P., Armstrong V.W., Brunet M., et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 2009, 31(2):139-152.
67. Madabushi R., Frank B., Drewelow B., et al. Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol 2006, 62(3):225-233.
68. Borcherding S.M., Baciewicz A.M., Self T.H. Update on rifampin drug interactions. II. Arch Intern Med 1992, 152(4):711-716.
69. Ruffmann C., Bogliun G., Beghi E. Epileptogenic drugs: a systematic review. Expert Rev Neurother 2006, 6(4):575-589.
70. Bunnag S., Vareesangthip K., Ong-ajyooth L. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation. JMed Assoc Thai 2006, 89(Suppl 2):S228-S234.
71. Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 2007, 22(5):328-335.
72. McHutchison J.G., Manns M.P., Muir A.J., et al. Telaprevir for previously treated chronic HCV infection. NEngl J Med 2010, 362(14):1292-1303.
73. McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. NEngl J Med 2009, 360(18):1827-1838.
74. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. NEngl J Med 2011, 364(13):1195-1206.
75. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. NEngl J Med 2011, 364(13):1207-1217.
76. Garg V., van Heeswijk R., Lee J.E., et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011, 54(1):20-27.
77. Hulskotte E., Gupta S., Xuan F., et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012, 56(5):1622-1630.
78. Werner C.R., Egetemeyr D.P., Lauer U.M., et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl 2012, 18(12):1464-1470.
79. Pungpapong S., Aqel B.A., Koning L., et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013, 19(7):690-700.
80. Yong T.Y., Lau S.Y., Li J.Y., et al. Medication prescription among elderly patients admitted through an acute assessment unit. Geriatr Gerontol Int 2012, 12(1):93-101.
81. Aithal G.P., Watkins P.B., Andrade R.J., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011, 89(6):806-815.
82. Fontana R.J., Watkins P.B., Bonkovsky H.L., et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009, 32(1):55-68.
83. Hassan Q., Roche B., Buffet C., et al. Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha. Transpl Int 2012, 25(9):941-947.
84. Suzuki Y., Ikeda K., Suzuki F., et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. JHepatol 2013, 58(4):655-662.
85. Fontana R.J., Hughes E.A., Appelman H., et al. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl 2012, 18(9):1053-1059.